By Fineline Cube 
Pfizer Inc. (NYSE: PFE) reported first quarter 2026 financial results on May 5, 2026, with total revenues reaching $14.5 billion, representing 2% year-over-year operational growth. Excluding Comirnaty (COVID-19 vaccine) and Paxlovid (oral antiviral), the company achieved 7% operational revenue growth, demonstrating strong underlying business momentum.
Financial Performance Summary
| Metric | Q1 2026 | YOY Change |
|---|---|---|
| Total Revenues | $14.5 billion | +2% operational |
| Ex-COVID Revenues | Not disclosed | +7% operational |
| Full-Year 2026 Revenue Guidance | $59.5–62.5 billion | Reaffirmed |
The operational growth was primarily driven by strong performance across multiple key products including Padcev, Eliquis, and several other therapeutic categories, partially offset by expected declines in COVID-19 product revenues.
Key Product Performance Highlights
| Product | Q1 2026 Revenue | Operational Growth | Key Drivers |
|---|---|---|---|
| Padcev (enfortumab vedotin) | $591 million | +39% | Increased market share in 1L la/mUC; launch momentum in cisplatin-ineligible MIBC |
| Eliquis (apixaban) | $2,166 million | +8% | Continued strong anticoagulation market leadership (co-commercialized with BMS) |
| Vyndaqel Family (Vyndaqel/Vyndamax/Vynmac) | $1,602 million | +4% | Stable ATTR amyloidosis treatment demand |
| Lorbrena (lorlatinib) | $305 million | +32% | Increased patient share in 1L ALK+ mNSCLC |
| Xeljanz | $180 million | +34% | Strong arthritis franchise recovery |
| Abrysvo (RSV vaccine) | $180 million | +31% | Global RSV vaccination program expansion |
Strategic Business Segments Analysis
- Oncology Portfolio: Padcev’s exceptional 39% growth reflects successful commercial execution in urothelial cancer indications, while Lorbrena continues to gain share in ALK-positive lung cancer
- Cardiovascular Franchise: Eliquis maintains its position as the leading anticoagulant with solid 8% growth, supported by ongoing co-commercialization with Bristol Myers Squibb
- Rare Disease Segment: Vyndaqel family demonstrates consistent performance with 4% growth in the ATTR amyloidosis market
- Inflammation & Immunology: Xeljanz shows remarkable 34% recovery, indicating improved market access and physician confidence
- Vaccines: Abrysvo’s 31% growth validates expanding global RSV vaccination programs across adult populations
Forward Outlook & Guidance
Pfizer has reaffirmed its full-year 2026 financial guidance, projecting total revenues in the range of $59.5 to $62.5 billion. The company’s ability to deliver 7% operational growth excluding COVID-19 products demonstrates the resilience and diversification of its core pharmaceutical portfolio.
Key growth catalysts for the remainder of 2026 include:
- Continued Padcev market penetration in bladder cancer indications
- Seasonal RSV vaccination campaigns driving Abrysvo sales
- Potential new indication approvals across the oncology and rare disease portfolios
- Ongoing international expansion of key franchises
Forward-Looking Statements
This brief contains forward-looking statements regarding financial performance, product sales, and guidance. Actual results may differ due to risks including competitive pressures, regulatory changes, and market dynamics.-Fineline Info & Tech